Materials and Methods

• Samples from 146 NSCLC patients treated with second line (2L) pembrolizumab or nivolumab were processed.
  • For each patient, a total of 12 WIFs from pre- and post-treatment biopsies, sequentially stained for H&E, CD3, CD8, CD163, CD137 and PD-L1 IHC were assessed (six pre- and six post-treatment).
  • In addition, whole sequencing data of pre-treatment biopsies was collected and analyzed for 62 patients.
  • Clinical outcomes included overall response (OR), progression-free survival (PFS), and overall survival (OS) of patients.

Clinical outcome prediction

Univariate analysis

Multivariate analysis

Conclusion

References